Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-06

Clinical Trial Update: HexafluOride, a Contrast Agent for Placenta Echo-angiography [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating HexafluOride as a contrast agent for placenta echo-angiography has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HexafluOride

Snippet

Sponsor: Centre Hospitalier Régional Metz-Thionville | Conditions: Pregnancy | Phase 3 | Status: COMPLETED